Arecor Therapeutics PLC (AIM:AREC) Chief Business Officer Manjit Rahelu speaks to Thomas Warner from Proactive after the biopharmaceutical group announced a significant development from its Specialty Hospital division.
A new collaboration with an unspecified "global medical products company" will focus on reformulating a blockbuster oncology drug into a ready-to-use liquid form, enhancing its efficiency and ease of use for patients.
This marks a significant shift from its powdered form, which was complex and time-consuming to prepare. The reconstituted drug is not only more convenient but also aims to reduce waiting times for patients, thereby improving overall healthcare delivery. Dr. Rahelu highlighted the collaborative effort involving a global partner with expertise in R&D, manufacturing, commercialisation, and regulatory affairs.
This partnership aims to leverage both entities' strengths, combining Arecor's innovative in-house development with the partner's global capabilities. Arecor's technology has been instrumental in this advancement, underscoring their capability to apply their technology across various therapeutic areas beyond diabetes.
This development is the second major outcome from Arecor's in-house pipeline and Rahelu says it demonstrates Arecor's ability to independently identify and develop promising candidates, translating R&D efforts into value-driving collaborations.
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/arecor-therapeutics-reveals-deal-with-global-medical-products-company-231525022